Compare Goldman Sachs Group Inc (GS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Moderna, Inc. — how do they compare? Goldman Sachs Group Inc trades at $895.32 (market cap $256.98B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Goldman Sachs Group Inc is far larger — about 3.3× Moderna, Inc.'s market cap, and Goldman Sachs Group Inc pays a 2.27% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and Moderna, Inc. for 59 Days on average.
| GS | MRNA | |
|---|---|---|
Market Cap | $256.98B | $78.65B |
Volume | 1,748,426 | 37,373,437 |
Sector | Financials | Health |
52-Week High | $1.15K | $225.00 |
52-Week Low | $744.60 | $22.36 |
Typical Hold Time | 101 Days | 59 Days |
Enterprise Value | $814.98B | $74.80B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $882.59, down 0.52% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows strong profitability with a 31.68% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights CEO David Solomon's focus on expanding earnings and building a durable revenue base, while the FICC business is expected to soften in Q3 2026.
The stock presents a mixed outlook: attractive valuation with a P/E of 13.63 and consensus price target of $1,130 suggests upside, but negative operating cash flows and high debt levels pose risks. Analyst sentiment is cautious with 40% buy ratings, while institutional interest remains steady. Key catalysts include revenue growth in asset and wealth management, but macroeconomic volatility and competitive pressures could hinder performance.
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
